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Chapter 1: Introduction
Tissue engineering was once categorized as a sub-field of biomaterials, but
has recently grown into a field of its own. It uses a combination of cells, engineering,
and materials to improve or replace biological functions. Tissue engineering has
been defined as an interdisciplinary field that applies the principles of engineering
and life sciences towards the development of biological substitutes that restore,
maintain, or improve tissue function or a whole organ1. It is understanding the
principles of tissue growth, and applying this to produce functional replacement
tissue for clinical use.1
While most of the aim for tissue engineering is to provide clinical therapies,
there are additional applications that can be used to provide valuable information
for evolving research. One application pursued by our lab, and referred to as an invitro blood vessel mimic (BVM), aims to use tissue-engineered constructs for invitro evaluation of devices and therapies.2 This blood vessel mimic is used to test
and evaluate intravascular devices and disease treatments. The BVM is used to
create a bench top model for testing between in-vitro bench top testing and early
animal test models.
Within the Tissue Engineering Group at Cal Poly, San Luis Obispo, there have
been numerous advances on the original BVM model which will allow us to explore
new approaches for creating a more physiologic in-vitro tissue engineered blood
vessel mimic (ultimate goal). This includes the research done on the investigation of
the effects of hyperglycemia (high glucose) on the blood vessel mimic. This BVM
consisted of human umbilical vein endothelial cells (HUVECs) on expanded
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polytetrafloroethlyene (ePTFE) to understand the characteristics of how HUVECs
will react to increased
creased hyperglycemic concentrations.
The main reason that these BVMs were developed is because of
cardiovascular disease. Cardiovascular disease is the class of diseases that involve
the heart or blood
ood vessels. One example is atherosclerosis, which is a condition in
which an artery wall thickens as a result of the accumulation of fatty materials such
as cholesterol and plaque. It is a chronic inflammatory response in the walls of the
arteries cause by accumulation of macrophage white blood cells, and promoted
prom
by
low-density
density lipoproteins without being able to remove fats and cholesterol from the
macrophages by high-density
density lipoproteins. This causes narrowing and hardening of
the arteries, and restricts blood flow that can lead to necrosis, heart disease, stroke,
st
and myocardial infarction3. As a result, 1 in 3 people will die
ie from cardiovascular
disease.3

Figure 1:: Normal artery (left), artery narrowed by atherosclerotic plaque (right)

There are many common risk factors specifically for cardiovascular disease,
disease
including high cholesterol, high blood pressure, smoking, diabetes, obesity, limited
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physical activity, age, and genetic propensity, which can all contribute to the
accelerated onset and premature effects of atherosclerosis.4
A common co-morbidity, and an additional focus of this project, is diabetes.
Diabetes is a group of metabolic diseases in which a person has high blood sugar,
either because the body does not produce enough insulin, or because cells do not
respond to the insulin that is produced. The high blood sugar produces the classical
symptoms of polyuria (frequent urination), polydipsia (increased thirst), and
polyphagia (increased hunger).
There are three main types of diabetes. Type 1 diabetes is characterized by
loss of the insulin producing beta cells of the islets of Langerhans in the pancreas
leading to insulin defiency.5 It is classified as immune-mediated, where beta cell loss
is a T-cell mediated autoimmune attack. Most people affected are healthy and often
are children (there are adult cases as well). There is no preventive measure against
type 1 diabetes, so it is difficult to say who will be affected by it.
Type 2 diabetes is characterized by insulin resistance; it is a condition where
cells fail to use insulin properly. In early stages of type 2 diabetes, the predominant
abnormality is reduced insulin sensitivity, where hyperglycemia can be reversed by
a variety of measures and medications that improve insulin sensitivity.5
The third type is gestational diabetes, which is similar to type 2 diabetes. It
involves inadequate insulin secretion and responsiveness, and occurs in about 2-5%
of all pregnancies. It is treatable and requires careful medical supervision because
20-25% of affected women develop type 2 diabetes later in life6.
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Insulin is the principle hormone that regulates the uptake of glucose from the
blood into most cells. Deficiency of insulin or the insensitivity of its receptors plays a
central role in all forms of diabetes.
With regard to cardiovascular disease, including for those patients that also
suffer from diabetes, there are different medical treatments available for
atherosclerosis that includes different medication with altered lifestyles and
physical intervention. These methods involve invasive replacement surgery or
minimally invasive catheter based procedures. Physical treatments that are helpful
in the short term include minimally invasive angioplasty procedures that include
stents to physically expand narrowed arteries7. Angioplasty is a technique of
mechanically widening a narrowed or obstructed blood vessel. It consists of an
empty and collapsed balloon on a guide wire, known as a balloon catheter, which is
passed into the narrowed locations and then inflated to a fixed size using saline
pressure. The balloon crushes the fatty deposits, opening the blood vessel for
improved flow. The balloon is then deflated and withdrawn. A metal stent is usually
deployed following the dilation to help maintain proper flow and mechanical
characteristics of the diseased vessel8.
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Figure 2:: Angioplasty and stent deployment into a blocked artery6

Minimally invasive treatments have shown mixed results, as past experiences
treating simple to complex lesions resulted in restenosis for as many as fifteen to
sixty percent of percutaneous coronary intervention.9 Restenosis is the reduction in
diameter of the vessel lumen following intravascular procedure, and is the result of
the cellular response to the injury imparted by balloon dilation and the stresses of
the stent pressing against the vessel walls. Pharmaceutical compounds and drugdrug
eluting stents (DES) have been developed to reduce the effects of restenosis,
however, continued study is required to conclusive
conclusively
ly determine the long-term
long
effectiveness of these therapies
therapies.9
Diabetic patients have an increased risk of restenosis after balloon
angioplasty, resulting in increased late morbidity and mortality, compared to nonnon
diabetic patients.10 Baree metal stents have been used as a method of intervention to
improve blood circulation,
ulation, but it has been shown that diabetes affect the
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development of restenosis after the intervention.11 Drug eluting stents slowly
release a drug to block cell proliferation, which, it prevents restenosis that could
block the stented artery. They are a more effective treatment than bare metal stents,
and have shown increased lifespan.11 Randomized, double-blind study, the
implantation of a slow-release, polymer-based, paclitaxel-eluting stent reduced the
risk of clinical and angiographic restenosis as compared with the implantation of a
bare-metal stent, in patients with a wide range of previously untreated coronary
lesions.12
There is an established relationship between heart disease and diabetes.
Although the main factor behind this relationship is unknown, hyperglycemia,
abnormal lipid metabolism, and insulin resistance, coupled with frequently
occurring hypertension results in acceleration of the atherosclerotic process; where
coronary artery disease is responsible for three-quarters of diabetes-related
deaths.13
Stent testing for coronary artery disease must understand the rules and
regulations that it follows by the United States Food and Drug Administration (FDA).
Preclinical testing is necessary to show that a product to market is safe and
effective. Some of these testing include bench top testing, in-vitro testing, and
animal studies. Bench top testing will usually measure things such as stress and
fatigue for medical devices to ensure that they can withstand physiologic forces
upon it and to be sure it can maintain the mechanical integrity. In-vitro testing uses
cells to test for biocompatibility, to be sure that the cells are able to live in the
exposed environment.
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For animal studies, researchers usually study rabbits, and move to larger
animals depending on the different factors.14 For intravascular devices, porcine
studies often serve as the final preclinical model due to anatomical similarities.14
Since it is relatively expensive to conduct and maintain animal testing facilities, the
development of the BVM can be of great use and importance. It will allow
researchers to gather more information and data at a more cost effective rate before
progressing onto animal models. The BVM consists of a biochamber, a peristaltic
pump, media reservoir, and connecting tubing and fittings, as illustrated in Figure 3.
The biochamber is used as a housing unit for the intended scaffold used, it (ePTFE)
that will act as the coronary artery. The biochamber will also contain media that will
act as the blood, to supply the cells with nutrients. The peristaltic pump is used to
allow for the flow of media through the system. The media reservoir supplies the
system with media, and the connecting tubing and fittings attaches the system
together.

Figure 3: SolidWorks model of the BVM system

With cardiovascular disease being a serious threat to human life, the field of
tissue engineering is emerging and growing rapidly with numerous discoveries and
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inventions. The use of a stent can assist with atherosclerosis by restoring proper
flow through diseased vessel. With the new and current research in drug eluting
stents, research has shown promising results, increasing the life expectancy of the
individual. Even though stents are useful, diabetic patients are at a higher risk of
restenosis as compared to non-diabetic patients when receiving a stent. Using the
BVMs, research can potentially be conducted in a “normal” and “hyperglycemic”
environment (without stents) and the results were compared against one another.

Objectives:
The main goals objectives of the experiments performed are as follows:
Develop and characterize a hyperglycemic environment for the BVM.
Determine target hyperglycemic values
Establish a diabetic “recipe,” amount of glucose in media.
Establish method to measure hyperglycemia in BVMs
Assess a normal and diabetic environment of a coronary artery by incorporating
hyperglycemia in BVMs.
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Chapter 2: Effects of Glucose on HUVEC Culture
Before setting up and performing experiments on the BVMs, proper glucose
concentrations needed to be calculated. A static experiment was performed, using
hyperglycemic media and HUVECs in petri dishes, to test for different glucose
concentrations to determine which concentration will be able to keep the cells alive.
This experiment will also give information on which concentration to use for the
BVM experiment.
Literature review was done on glucose concentrations in diabetic patients,
and values produced by Mediratta et al. are as followed15:
•
•
•
•

Normal Patients 80-120 mg/dL
Moderate 130-160 mg/dL
High 180-200 mg/dL
Extreme 250 mg/dL
With this new information, appropriate amounts of glucose needed to be

added to HUVEC media to obtain the different glucose concentrations. To do this, we
used the HUVEC media, which contained 500mL EBM2 and EBM2 kit from Lonza.
After filter sterilizing it, Sigma G6152 D-(+) Glucose from Sigma was added to the
media. Note that the cell media does not contain the same properties as blood.
•
•
•
•
•

Control – Normal HUVEC media
o 20 mL of HUVEC media
Low concentration – 0.01 g/mL
o 20 mL of HUVEC media + 0.2 g of glucose
Moderate concentration – 0.014 g/mL
o 20 mL of HUVEC media + 0.28 g of glucose
High concentration – 0.019 g/mL
o 20 mL of HUVEC media + 0.38 g of glucose
Extreme concentration – 0.025 g/mL
o 20 mL of HUVEC media + 0.5 g of glucose
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nt of glucose does not include the amount of glucose present in the base
*The amount
media. The amount listed was in addition to the base media formulation.
To test that these concentrations were indeed correct, a glucose monitor was
used.. Using the glucose monitor, the test strips were submerged into the HUVEC
media and glucose solution after a thorough mixing. Then, the
he media was sterilized
using an autoclave at 121oC for thirty minutes
minutes. All solutions were the proper
pro
concentrations.

Figure 4:: Glucose meter to determine proper concentrations

Once the proper concentrations were determined, the next step was to add
the glucose/media solution to HUVEC
HUVECs and evaluate how the cells respond to
increased glucose concentration. See Appendix A for protocol.
From this static experiment, HUVEC characteristics were determined in the
presence of increased glucose concentration
concentrations. The two plates used were identical,
contained the same glucosee concentration in each well with the same cells. The
results were consistent with each other; the different concentrations had the same
effects on the cells from the different plates. There were not any contamination
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issues. Using an inverted light microscope with a camera, the results are as follows
from 24, 48, 72, 96, 120 hours. The images presented are for day 1 and day 5, the
beginning and end of the experiment.
For normal concentration, the control:

Figure 5: Day 1 with normal concentration

Figure 6: Day 5 with normal concentration

No glucose was added, but still ended up with significant cell death due to lack of
nutrients by day 5.
For low concentration, 100 mg/dL:

Figure 7: Day 1 of low concentration
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Figure 8: Day 5 of low concentration

Low glucose concentration had minimal effect on cell death.

For medium concentration, 140 mg/dL:

Figure 9: Day 1 of medium concentration

Figure 10: Day 5 of medium concentration

Medium glucose had an increased amount of cell death (decreased proliferation)
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For high concentration, 190 mg/dL:

Figure 11: Day 1 of high concentration

Figure 12: Day 5 of high concentration

High glucose had a high cell death rate, lack of proliferation, and cellular
morphology seemed to change.
For extreme concentration, 250 mg/dL:

Figure 13: Day 1 of extreme concentration
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Figure 14: Day 5 of extreme concentration

Extreme glucose concentration had a high cell death rate, lack of proliferation,
morphology seemed to change just like the high glucose concentration.
It is apparent that an increase in glucose concentration in the HUVEC media
had an effect on HUVECs, showing an apparentdecrease in cell proliferation, change
in cellular morphology, and increase in cell debris. The “age” (the passage of the
cells) could have also played a role in how the cells reacted to the glucose. The
concentration that seemed most appealing to use in the BVM set up would be
somewhere between low and medium concentrations. A concentration like
120mg/dL would be the best to use, which is 6 g for 500 mL of media. It would be
the best concentration to use because it did not have much cell death.
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Chapter 3: Hyperglycemic Blood Vessel Mimic
As noted in the introduction, diabetic patients react differently toward stent
implantation as compared to “normal” patients. There is a higher risk of restenosis
with diabetic patients.16 Experiments were performed using the already existing
BVM that previous students have developed, using a few modifications, to test the
hypothesis that hyperglycemia has an effect on HUVECs in a BVM. The modifications
were changing the HUVEC media to incorporate the different glucose concentration
and compare it to a normal concentration to determine if there is a difference in
HUVEC characteristic. See Appendix B for protocol for experiment performed.

Figure 15: BVM set up with biochamber, pump, and reservoir.
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Figure 16: Biochamber with the ePTFE grafts and media.

To analyze the results: bisbenzimide (BBI) was used for en face evaluation and
histology was performed for cross-sectional assessment. See Appendix C for BBI
protocol, and Appendix D for histology protocol.

Results from Hyperglycemic BVM experiment:
Using BBI and histology evaluation, images were obtained to identify and
analyze if increased glucose concentration played a role in HUVEC characteristics
during a BVM experiment. There results are as follows:

Figure 17: BBI image of a normal vessel after 1 day.
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Figure 18: Histology image of a normal vessel after 1 day.

These images show that the normal vessel after one day had a minimal lining
of HUVECs around the lumen of the scaffold. This was used as a control to compare
against the one day hyperglycemic vessel.

Figure 19: BBI image of a hyperglycemic vessel after 1 day.
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Figure 20: Histology image of a hyperglycemic vessel after 1 day

These images show that after one day, the increased glucose concentration in
the media potentially affected the HUVECs slightly. There seems to be more section
on the vessel with less cells, seen on the BBI images. Also there are small gaps in the
lining on the histology image.

Figure 21: BBI image of a normal vessel after 3 days.
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Figure 22: Histology image of a normal vessel after 3 days.

These images of the normal vessels after 3 days showed a confluent lining as
seen in the histology images (slightly more confluent than at day one). The BBI
image also shows an abundance of cells on the surface of the scaffold, though there
are some patches of no cells.

Figure 23: BBI image of hyperglycemic vessel after 3 days.
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Figure 24: Histology image of hyperglycemic vessel after 3 days.

These images show that increased glucose concentration in the media may
be detrimental to the characteristics of the HUVECs. The BBI images showed less
proliferation of the cells as compared to the BBI image of the 3 day normal vessel. In
the histology image, it does not have a confluent lining around the inner lumen of
the scaffold and it seems to be as if the cells were group/clumping together.

Conclusion about findings:
For the vessels at 1 day, for both the normal and hyperglycemic, they showed
minimal cell coverage throughout the scaffold. The results were similar between the
two, but the hyperglycemic vessel was not quite as confluent as the normal vessel in
the BBI and histology images.
For the vessels at 3 days, the normal and hyperglycemic vessels showed
slightly more cell coverage across the scaffold. But after 3 days for the
hyperglycemic vessel, there appeared to be a decrease in cell density, and it
appeared as if the cells were balling/clumping up around the inner lumen of the
scaffold.
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These results indicate that glucose concentration affects cellular
characteristics and are consistent with the results from the static experiment of
adding media with different concentrations of glucose to cells.
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Chapter 4: Discussion and Conclusion
Tissue engineering is an emerging field that has potential for novel and
unmatched medical therapies and treatment. There is also a field of tissue
engineering that has another form of application, an application to utilize tissue
engineered constructs for in-vitro evaluation of medical devices and therapies. In
vitro blood vessel mimics were created to perform bench top testing that can be
used to test for vascular disease treatments and intravascular devices. The BVM
could minimize the development time for emerging technologies and be more cost
efficient. The blood vessel mimic incorporated in this study was a combination of
previous experiments, but incorporating increased glucose concentrations.
For future work, it would be helpful to perform another static experiment
with the different glucose concentrations compared to normal concentration (with
the possibility of performing it concurrently with the BVM set up). This next
experiment should perform a live/dead stain to determine if the cells are actually
alive. This would help determine if the increased glucose concentration actually kills
the cells.
Another BVM set up could also be performed with normal HUVEC media in
the reservoir first, before switching to the hyperglycemic media. It will be known
that the cells are given the nutrients needed to survive, and switching the media to
have 3, 4, and 5-day time points would show if the glucose has the same affect as
being first exposed to the cells. The first three days will have the normal media.
There is also the possibility to apply a more diabetic condition to the BVM such as
geometry, flow rate, etc. Blood flow rate in diabetic patients is different that normal
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patients. Increased blood glucose levels and large fluctuations in these levels are
associated with an increased incidence of diabetic retinopathy and are known to
affect retinal hemodynamics in diabetic patients.17 In a study conducted, the total
retinal volumetric blood flow rate in diabetic patients was significantly larger than
normal by 23%.18 The results also showed larger-than normal veins in diabetic
patients.18
Overall, the work complete indicates that glucose concentration has an effect
on HUVECs in culture which can bpotentially provide a model for stent implantation
in a diabetic patient as compared to a normal patient.
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Appendix A
Static Experiment to Test the Effects of the Different Concentrations of
Hyperglycemic Media on HUVECs Protocol.
•

•

•

•

•

•

•

Thaw out cells. Taking the frozen 1mL solution and placing it into the water
bath until thawed. Under the hood, adding 12 mL HUVEC media to a T75
flask and then adding the 1 mL cells solution. Place in 37oC incubator
overnight.
For passing the cells the next day, obtain the T75 and pass it 1:3. Aspirate the
media in the flask using the vacuum pump, followed by rinsing with DCF-PBS
and then aspirate again. Add 3 mL of trypsin after it had been thawed and
vortexed and let sit for approximately 2 minutes. Apply force to the flask if
necessary to remove the cells from the surface. Deactivate with 5 mL of
HUVEC media and then mix. Put all 8 mL in a prepared T225 flask that has 30
mL of HUVEC media (total of 38 mL of cell solution). Place in incubator for 2
days.
After 2 days, take the T225 flask and aspirate off the cell solution media using
the vacuum. Then rinse with DCF-PBS and aspirate again. Add 9 mL of
trypsin after it had been thawed and votrexed and let it sit for approximately
3 minutes. Apply force to the flask if necessary to remove the cells from the
surface. Deactivate with 9 mL of HUVEC media and then mix. Place 9 mL of
cell solution into 1 T225 flask that is prepared with 30 mL HUVEC media and
the another 9 mL of cell solution into another T225 flask that is prepared
with another 30 mL HUVEC media. Place in incubator for 3 days.
Before the initial set up experiment, place 20 mL HUVEC media into 50 mL
tubes (4 times, one for each glucose concentration). Add the corresponding
glucose amount to each labeled tube and mix thoroughly Filter sterilize
media using a 5 µm filter and syringe into another 50 mL tube. Place in
incubator until ready to start the experiment.
Obtaining two 6-well plates, added the cell solution into each well, one T225
for each plate. For each T225 flask, aspirated the cell solution, rinsed with
DCF-PBS, added 9 mL trypsin, deactivated with 9 mL HUVEC media, mixed,
and then added 3 mL solution for each well. Placed in incubator overnight.
Obtain the two 6-well plates with the HUVEC and the HUVEC media with
different concentrations of glucose. Correctly mark where each concentration
will be. Add 5 mL of each concentration to each well. Take a picture of each
well and document findings. Place back in incubator overnight (or intended
time point).
For each intended time point, take plates out of incubator and record
findings, pictures and description. If anytime points are longer than 3 days,
be sure to change the media (correct media in each well!).
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Appendix B
Hyperglycemic Blood Vessel Mimic Experiment Protocol
For preparation one week prior to the set up:
•

•
•
•

Gas sterilize the biochambers, lids, 2-port reservoirs, and the necessary
tubing and fittings at the vet clinic (this must be done over the weekend
because of dangerous fumes).
Determine the number of cells needed and the passage schedule to obtain
target cells. Thaw the cells and pass them according to schedule.
Obtain ePTFE grafts, mount them on the proper fittings, and suture them
onto fittings.
Autoclave ePTFE grafts, flasks for degassing media, and forceps that are in
the proper packaging.

Preparation the day before the set up:
•

•

Make the necessary media
o HUVEC media
 500 mL EBM2 and kit from Lonza
o HUVEC media with added glucose
 500 mL EBM2 plus 0.012 g/mL (2 g for 500 mL of media)
 Autoclaved base media with glucose at Applied Biotechnology
Institute (30 minute cycle)
 After media has cooled, add kit from Lonza after media has
cooled down
o Bioreactor media
 500 mL M199, 56 mL FBS, 5 mL L-glutmine, 5 mL P/S, 0.6 mL
Fungizone, 2.8 mL Hepes
o Conditioning media
 500 mL M199, 83 mL FBS, 5 mL P/S, 0.6 mL Fungizone.
Denucleate ePTFE grafts (using filtered EtOH) after autoclave
o Start my degassing conditioning media in the flask with the vacuum
pump attachment. Degass for approximately 30 minutes
o Take autoclaved ePTFE grafts and add them to 70% EtOH for 15
minutes. Each graft will be in a separate 15 mL tube.
o Transfer grafts, using sterile forceps, to 100% EtOH for 15 minutes or
until grafts turn “clear”. Agitate if necessary. Each graft will be in a
separate 15 mL tube.
o Take degassed conditioning media and add to 15 mL tubes.
o Using sterile forceps, take graft from 100% EtOH and transfer it to the
degassed media tubes.
o Place in 35oC incubator overnight.
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Set up day:
•
•
•
•
•
•

•
•
•

•
•

•

•
•

Warm up bioreactor media, conditioning media, and HUVEC media.
Fill the biochambers with the bioreactor media. Make sure that the fittings
are closed off.
Once the biochambers are filled to the appropriate level, insert the sterile
grafts into the biochamber. Be sure to keep everything sterile.
Using sterile gloves, attach the fittings from the grafts onto the biochamber
fittings.
Number the corresponding biochamber lids with the correct number using a
tape and marker.
Using a syringe filled with conditioning media, attach it to the fitting
connected to the biochamber and flush the lumen to prime the graft. Clamp
the lumen and continue to prime the graft. Repeat for all of the grafts.
Add conditioning media to the two port reservoirs, enough to where the
tubing is submerged. Connect the fittings to the biochamber fittings.
Turn on the CO2 and prep the incubator (clean shelves and plug in the pump).
Once everything is prepped, bring the biochamber with the reservoir into the
incubator and attach it to the pump. Allow the media to flow through the
lumen first to remove air bubbles, and then clamp the lumen to allow for
transmural flow for 10 minutes at 150-rpm.
Leave the primed biochambers in the large incubator until the cells are ready
to sod the grafts.
Prep the 2-port reservoir with HUVEC media with the different glucose
concentrations (make sure they correspond with the appropriate numbers).
Prepare one for each vessel and make sure that the drip is visible and the
outlet is submerged in the media. Clamp the tubing and leave in the
incubator until the cell-sodding step.
Harvest the cells from the T225s.
o Aspirate media using vacuum
o Rinse with DCF-PBS and aspirate
o Apply the appropriate amount of trypsin, agitate and mix to make
sure all the cells are removed from the surface.
o Deactivate with HUVEC media
o Take the cell solution and add to 50 mL tube
o Centrifuge solution on setting 4 for 4 minutes
o Aspirate supernatant, do not aspirate the pellet at the bottom
o Resuspend the pellet using appropriate amount of HUVEC media.
o Prepare one trough of HUVEC media and one trough with the cell
solution.
Remove biochambers and reservoirs from incubator and place them in the
hood, prep for cell sodding.
For each vessel:
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•
•
•
•

•

•

o Prime each graft by injecting 5 mL of HUVEC media using a syringe
while capping off the proximal stopcock so the fluid will not flow back
into the reservoir. Close off the stopcock and remove the syringe.
o Using a syringe, take up 4 mL of the cell solution and attach it to the
stopcock. Inject the cell solution at a very moderate rate. Once it is
about to finish, cap off stopcock and detach the syringe.
o Chase the cells with 4 mL HUVEC media using the syringe.
o Replace the old reservoir with the new HUVEC media with different
glucose concentrations. Be sure to tighten the reservoir caps.
o Move the BVM system into the incubator and attach it to the pump.
Maintain transmural flow at 10 rpm for 30 minutes.
After 30 minutes, stop transmural flow and maintain luminal flow at 15 rpm
for 24 hours.
If necessary, remove BVM at 24 hours, and adjust the luminal flow 10-15 rpm
at a time until it reaches 90 rpm.
Replace reservoir media every 3rd day if the experiment runs more, and be
sure to check the CO2 level. Make sure that none of the bioreactors are
leaking media.
Take down each vessel at designated time points and cut the ePTFE grafts off
the fitting, and using sterile procedure, place them into a tube filled with
histochoice.
Leave in histochoice until ready for evaluation.
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Appendix C
BBI Evaluation protocol (by Dalton Chavez):
•
•
•

•

•

•
•

•

Begin by wrapping a nonsterile 15 mL tube in foil, not allowing light in.
Thoroughly label all tube for all the samples.
Make the BBI solution, be sure to always keep the stock solution wrapped in
foil to keep light out.
Use a small stock solution (acquired in the refrigerator and dilute 1:1000
with milli-Q water (10 µl stock solution in 10 mL water). Use the pipette aid
for the milli-Q water, and then spray it down with EtOH before replacing it.
Mix the solution by inverting it.
The each sample using a blade, being careful not to disrupt the cell lining
inside the lumen (squeezing, touching, and scraping can disrupt the lining
and ruin the experiment.
Using clean forceps, place the ePTFE grafts in the corresponding 15 mL tubes
that contain the BBI solution. Carefully keep track of samples, and leave in
BBI solution for at least 15 minutes. Left in longer is better, but do not leave
in too long or cells will get bleached out.
Put away extra stock solution and clean up preparation area.
With the permission or help from Dr. Cardinal, use the fluorescent
microscope to obtain en face images. Take forceps and kimwipes to use at the
microscope.
When at the microscope, use the following steps to obtain images:
o Log into notebook (fluorescence, initials, date, time, and lamp hours).
o Turn turret to setting 4.
o Turn on Olympus lamp (green switch)
o Turn on Optiscan wheel (black switch)
o Turn on the camera (black switch)
o Set filter wheel 1 to 1, and set filter wheel 2 to 1.
o Open the shutter
o Set prior keypad to shutter S1.
o Dial objectives to desired magnification (typically 4x and 10x for BBI
images).
o Set thin bar icon of eye and camera
o Sign into the computer by clicking Kristen’s account (password can be
obtained from Kristen).
o Click QCapture Pro (on desktop)
o Click camera icon at top of QCapture Pro window.
o Place slide onto microscope, then place the sample to top of it.
o Manually adjust microscope to clarify the image.
o If scaffold is too wet, carefully blot end of scaffold on kimwipe.
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o Take pictures, and save to desired folder. Label samples with
information, initials, and magnification.
o Once finished, log out, shit down system by switching off Olympus
lamp, Optiscan wheel, and camera.
o Log out of notebook.
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Appendix D
Hematoxylin and Eosin (H&E) Staining Protocol
For acquisition of histology images:
Hematoxylin and Eosin ePTFE staining protocol:
•
•
•
•
•

•

•

Place desired samples in cassettes and set them in histochoice.
With the help of a laboratory technician, place samples in processor and run
it for 14 hours.
Remove samples and embed them into wax.
Samples are now ready for sectioning and staining.
To begin sectioning, start by preparing the area.
o Put on gloves, eye protection, and laboratory aprons.
o Place the blocks in the refrigerator.
o Turn on the oven.
o Turn on the small water bath by simply plugging it in. Do not adjust
the knob, and add distilled water.
o Place blade on the microtome. The blades can be found in the box next
to the microtome. Be careful, the blades are very sharp. Do not touch
the blade with anything, it will nick the blade and make it useless.
To begin sectioning:
o Take block from the refrigerator and secure it in the microtome
clamp.
o Adjust the levers to make sure the block face flesh is against the blade.
o Cut the sections of tissue blocks at 7 µm.
o Use the forceps to carefully place sections into the water bath.
o Pick up sections with a slide. The white part of the slide has a rough
and smooth side. Place sections only on the rough side.
o Using a pencil, label the slide with the following information: block
number, date, and initials.
o Place slides on the drying rack.
o Repeat sectioning to obtain 2-3 good slides.
To begin staining:
o Place the dry slides into staining rack (the small steel holder).
o Put the staining rack in the oven for 10 minutes or until the wax is
clear.
o While the slides are in the oven, clean the microtome station by
returning the blade, turn off the microtome, unplugging the water
bath, and disposing of the water.
o Pull the staining rack out of the over and allow it to cool for 5 minutes
(until some wax begins to show again).
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o During the waiting period, prepare the staining station by filling
dishes and organizing appropriately.
o Then begin the staining process. The rack will be dipped into each of
these staining dishes for the given time shown in the following order:
 5 minutes – Xylene (in hood)
 5 minutes – Xylene (in hood)
 2 minutes – 100% EtOH
 2 minutes – 100% EtOH
 2 minutes – 95% EtOH
 1 minute – Air Dry
 4 minutes – Hematoxlin
 1 minute – Distilled Water
 30-45 seconds – Clarifier
 1 minute – Distilled Water
 1 minute – Bluing
 1 minute – Distilled Water
 1 minute – 95% EtOH
 1 minute 30 seconds – Eosin
 1 minutes – 100% EtOH
 1 minutes – 100% EtOH
 5 minutes – Xylene (in hood)
 5 minutes – Xylene (in hood)
•

To begin cover slipping, performed in the hood after staining is complete:
o Pick up the slide with hemostats. Be careful because there is still
xylene on the slides
o Put a thin line of mounting glue along the long edge of one slide
o Take cover slip and place it slowly in the slide. Be sure not to slide
over the sample and damage it, and make sure there are no bubbles
and the sample is fully covered with the mounting glue.
o Repeat process for each slide, and let them dry on the tray.

•

To begin analyzing these samples (protocol by Dalton Chavez)
o With the permission or help from Dr. Cardinal, use the white-light
microscope to obtain the images of the samples mounted on slides.
o Log into notebook with the following information: white, initials, date,
time, and lamp hours.
o Turn turret to setting 1.
o Turn on Optiscan wheels (black switch).
o Turn on the camera (black switch).
o Set filter wheel 2 to 5.
o Open the shutter.
o Set prior keypad to shutter S1.
o Turn on the white light (black switch on the side of the microscope
are).
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o Dial objectives to desired magnification (typically 10x for histology
images of cell sodded scaffolds).
o Set the thin bar to icon of eye and camera.
o Sign into computer by clicking Kristen’s account (password can be
obtained from Kristen).
o Click QCapture Pro (on desktop).
o Click camera icon at top of QCapture Pro window.
o Place slide on the microscope. Use the joystick to move sample under
microscope lens. Use the dial on base of microscope to adjust
exposure of live image.
o Use course focus and fine focus on base of microscope to clarify live
image.
o Refocus image if desired. Click “Snap” to take pictures. Save to desired
folder, and label samples.
o Repeat this for the desired samples.
o Quit QCapture Pro and log out of computer.
o Shut down microscope by switching off Optiscan wheels, camera and
white light.
o Log out of notebook.
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